Posted by Michael Wonder on 19 Nov 2022
Inflation Reduction Act drug pricing provisions aren’t at all like price controls in Europe
18 November 2022 - The opposition to the prescription drug pricing provisions in the Inflation Reduction Act can be hyperbolic.
It’s common to hear detractors contend that the measures will “stifle innovation,” “devastate the biopharmaceutical industry,” and may “propel us light years back into the dark ages of medical research.”
